These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 22970224)
1. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. Duprez DA; Neuhaus J; Kuller LH; Tracy R; Belloso W; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon D; Paton NI; Prineas RJ; Neaton JD; PLoS One; 2012; 7(9):e44454. PubMed ID: 22970224 [TBL] [Abstract][Full Text] [Related]
2. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. Nordell AD; McKenna M; Borges ÁH; Duprez D; Neuhaus J; Neaton JD; ; J Am Heart Assoc; 2014 May; 3(3):e000844. PubMed ID: 24870935 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. Kuller LH; Tracy R; Belloso W; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Neuhaus J; Nixon D; Paton NI; Neaton JD; PLoS Med; 2008 Oct; 5(10):e203. PubMed ID: 18942885 [TBL] [Abstract][Full Text] [Related]
4. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. Ledwaba L; Tavel JA; Khabo P; Maja P; Qin J; Sangweni P; Liu X; Follmann D; Metcalf JA; Orsega S; Baseler B; Neaton JD; Lane HC; PLoS One; 2012; 7(3):e24243. PubMed ID: 22448211 [TBL] [Abstract][Full Text] [Related]
5. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. De Luca A; de Gaetano Donati K; Colafigli M; Cozzi-Lepri A; De Curtis A; Gori A; Sighinolfi L; Giacometti A; Capobianchi MR; D'Avino A; Iacoviello L; Cauda R; D'Arminio Monforte A BMC Infect Dis; 2013 Sep; 13():414. PubMed ID: 24004495 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Duprez DA; Kuller LH; Tracy R; Otvos J; Cooper DA; Hoy J; Neuhaus J; Paton NI; Friis-Moller N; Lampe F; Liappis AP; Neaton JD; Atherosclerosis; 2009 Dec; 207(2):524-9. PubMed ID: 19515371 [TBL] [Abstract][Full Text] [Related]
7. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. Neuhaus J; Jacobs DR; Baker JV; Calmy A; Duprez D; La Rosa A; Kuller LH; Pett SL; Ristola M; Ross MJ; Shlipak MG; Tracy R; Neaton JD J Infect Dis; 2010 Jun; 201(12):1788-95. PubMed ID: 20446848 [TBL] [Abstract][Full Text] [Related]
8. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. Baker JV; Neuhaus J; Duprez D; Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon DE; Paton NI; Neaton JD; J Acquir Immune Defic Syndr; 2011 Jan; 56(1):36-43. PubMed ID: 20930640 [TBL] [Abstract][Full Text] [Related]
9. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Wohl DA; Arnoczy G; Fichtenbaum CJ; Campbell T; Taiwo B; Hicks C; McComsey GA; Koletar S; Sax P; Tebas P; Ha B; Massengale K; Walsh K; Stein JH Antivir Ther; 2014; 19(2):141-7. PubMed ID: 23985706 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection. Gupta M; Miller CJ; Baker JV; Lazar J; Bogner JR; Calmy A; Soliman EZ; Neaton JD; Am J Cardiol; 2013 Mar; 111(5):760-4. PubMed ID: 23276469 [TBL] [Abstract][Full Text] [Related]
11. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Phillips AN; Carr A; Neuhaus J; Visnegarwala F; Prineas R; Burman WJ; Williams I; Drummond F; Duprez D; Belloso WH; Goebel FD; Grund B; Hatzakis A; Vera J; Lundgren JD Antivir Ther; 2008; 13(2):177-87. PubMed ID: 18505169 [TBL] [Abstract][Full Text] [Related]
12. Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. Grund B; Baker JV; Deeks SG; Wolfson J; Wentworth D; Cozzi-Lepri A; Cohen CJ; Phillips A; Lundgren JD; Neaton JD; PLoS One; 2016; 11(5):e0155100. PubMed ID: 27171281 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. Borges ÁH; O'Connor JL; Phillips AN; Neaton JD; Grund B; Neuhaus J; Vjecha MJ; Calmy A; Koelsch KK; Lundgren JD; J Infect Dis; 2016 Aug; 214(3):408-16. PubMed ID: 27132283 [TBL] [Abstract][Full Text] [Related]
14. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. Borges ÁH; Weitz JI; Collins G; Baker JV; Lévy Y; Davey RT; Phillips AN; Neaton JD; Lundgren JD; Deeks SG; AIDS; 2014 Jul; 28(12):1791-6. PubMed ID: 25003720 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. Porter BO; Shen J; Kovacs JA; Davey RT; Rehm C; Lozier J; Csako G; Nghiem K; Costello R; Lane HC; Sereti I AIDS; 2009 Sep; 23(15):2015-9. PubMed ID: 19617815 [TBL] [Abstract][Full Text] [Related]
16. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. Lucas GM; Cozzi-Lepri A; Wyatt CM; Post FA; Bormann AM; Crum-Cianflone NF; Ross MJ; HIV Med; 2014 Feb; 15(2):116-23. PubMed ID: 24024499 [TBL] [Abstract][Full Text] [Related]